IP Library › Granted Patent US 12,370,252
Granted Patent B2
US 12,370,252 · App. 17/289,827 · Granted Jul 29, 2025

RSV virus-like particles and methods of use thereof

Inventors: Binh Ha (Atlanta, GA); Larry J. Anderson (Atlanta, GA); Elizabeth R. Wright (Atlanta, GA)
Assignees: Emory University; Children's Healthcare of Atlanta; Wisconsin Alumni Research Foundation
A61K39/155A61K39/39C12N7/00C12N2760/18023C12N2760/18034
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,370,252
App. No.
17/289,827
Granted
Jul 29, 2025
Kind
B2
Abstract

The present disclosure relates to virus-like particles and vaccine compositions for inducing immunity and preventing respiratory syncytial virus (RSV) infection. Specifically, the disclosure provides virus like-particles (VLPs) for use in inducing immunity to respiratory syncytial virus (RSV) infections or symptoms thereof, wherein the VLP comprising a respiratory RSV matrix protein (M) and an RSV M2-1 protein, a glycoprotein (G), a fusion protein (F), and/or a phosphoprotein (P).

Claims (10)

1. A virus like particle (VLP) comprising a respiratory syncytial virus (RSV) M protein, an RSV P protein, an RSV F protein, and an RSV G protein, wherein

the RSV F protein comprises SEQ ID NO: 23 or

the RSV G protein comprises SEQ ID NO: 1.

2. The VLP of claim 1 , wherein the RSV F protein comprises SEQ ID NO: 23.

3. The VLP of claim 1 , wherein the RSV G protein comprises SEQ ID NO: 1.

4. The VLP of claim 1 , wherein the RSV G protein is a recombinant RSV G protein.

5. A vaccine comprising the VLP of claim 1 .

6. The vaccine of claim 5 , further comprising an adjuvant.

7. A method of inducing immunity to RSV infection or at least one symptom thereof in a subject, comprising administering one or more effective doses of the vaccine of claim 5 .

8. The method of claim 7 , wherein the one or more effective doses of the vaccine are administered to the subject via a route that is selected from the group consisting of an intramuscular route, a subcutaneous route, an intradermal route, an oral administration, a nasal administration, and inhalation.

Continuity (2)
Provisional Application 62751975 · Oct 29, 2018
Related Publication 20210401969A1 · Dec 30, 2021
References Cited (79)
US 8741311B2 · Wong · 2014 [cited by examiner]
US 8920812B2 · Haynes · 2014 [cited by applicant]
US 10899800B2 · Langedijk · 2021 [cited by examiner]
US 20080233150A1 · Smith et al. · 2008 [cited by applicant]
US 20110097358A1 · Galarza et al. · 2011 [cited by applicant]
US 20160102123A1 · Langedijk · 2016 [cited by examiner]
US 20170290906A1 · Compans et al. · 2017 [cited by applicant]
US 20170319682A1 · Smith et al. · 2017 [cited by applicant]
US 20190002537A1 · Perret et al. · 2019 [cited by applicant]
JP 2018007655A · 2018 [cited by applicant]
WO 2017055775A1 · 2017 [cited by applicant]
Walpita et al., PLOS One;10(7):e0130755 (Year: 2015). [cited by examiner]
Meshram et al., Journal of Virology vol. 90 No. 23, pp. 10612-10628 (Year: 2016). [cited by examiner]
Comparison to SEQ ID No. 3 (Year: 2024). [cited by examiner]
Comparison to SEQ ID No. 23 (Year: 2024). [cited by examiner]
International Search Report and Written Opinion for International Application No. PCT/US2019/058559 dated Feb. 27, 2020. [cited by applicant]
Cimica et al., Novel Respiratory Syncytial Virus-Like Particle Vaccine Composed of the Postfusion and Prefusion Conformations of the F Glycoprotein. Clin Vaccine Immunol. 2016, vol. 23(6), p. 451-9. [cited by applicant]
Mitra et al., The Human Respiratory Syncytial Virus Matrix Protein Is Required for Maturation of Viral Filaments. J Virol. 2012, vol. 86(8), p. 4432-43. [cited by applicant]
Meshram et al., The Respiratory Syncytial Virus Phosphoprotein, Matrix Protein, and Fusion Protein Carboxy-Terminal Domain Drive Efficient Filamentous Virus-Like Particle Formation. J Virol. 2016, vol. 90(23), p. 10612-… [cited by applicant]
Supplementary Partial European Search report, mailed May 25, 2022, received in connection with corresponding EP Patent Application No. 19873849.4. [cited by applicant]
International Preliminary Report on Patentability issued for Application No. PCT/US2019/058559, dated May 14, 2021. [cited by applicant]
Altschul, Stephen F., et al. “Basic local alignment search tool.” Journal of molecular biology 215.3 (1990): 403-410. [cited by applicant]
Altschul, Stephen F., et al. “Gapped BLAST and PSI-BLAST: a new generation of protein database search programs.” Nucleic acids research 25.17 (1997): 3389-3402. [cited by applicant]
Anderson LJ. Respiratory syncytial virus vaccine development. Seminars in immunology. 2013;25(2):160-171. [cited by applicant]
Bakker SE, Duquerroy S, Galloux M, et al. The respiratory syncytial virus nucleoprotein-RNA complex forms a left-handed helical nucleocapsid. J Gen Virol. 2013;94(Pt 8):1734-1738. [cited by applicant]
Beaucage, S. L., and M. H. Caruthers. “Deoxynucleoside phosphoramidites—a new class of key intermediates for deoxypolynucleotide synthesis.” Tetrahedron letters 22.20 (1981): 1859-1862. [cited by applicant]
Boyoglu-Barnum S, Gaston KA, Todd SO, et al. A respiratory syncytial virus (RSV) anti-G protein F(ab')2 monoclonal antibody suppresses mucous production and breathing effort in RSV rA2-line19F-infected BALB/c mice. J Vi… [cited by applicant]
Boyoglu-Barnum S, Todd SO, Chirkova T, et al. An anti-G protein monoclonal antibody treats RSV disease more effectively than an anti-F monoclonal antibody in BALB/c mice. Virology. 2015;483:117-125. [cited by applicant]
Boyoglu-Barnum S, Todd SO, Meng J, et al. Mutating the CX3C Motif in the G Protein Should Make a Live Respiratory Syncytial Virus Vaccine Safer and More Effective. J Virol. 2017;91(10). [cited by applicant]
Chirkova T, Boyoglu-Barnum S, Gaston KA, et al. Respiratory syncytial virus G protein CX3C motif impairs human airway epithelial and immune cell responses. J Virol. 2013;87(24):13466-13479. [cited by applicant]
Chirkova T, Lin S, Oomens AG, et al. CX3CR1 is an important surface molecule for respiratory syncytial virus infection in human airway epithelial cells. J Gen Virol. 2015;96(9):2543-2556. [cited by applicant]
Collins PL CJ. Respiratory syncytial virus and metapneumovirus. In: Fields virology, 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2007:1601-1646. Abstract. [cited by applicant]
Collins PL, Fearns R, Graham BS. Respiratory Syncytial Virus: Virology, Reverse Genetics, and Pathogenesis of Disease. In: Anderson LJ, Graham BS, eds. Challenges and Opportunities for Respiratory Syncytial Virus Vaccin… [cited by applicant]
Connors M, Collins PL, Firestone C-Y, Murphy BR. Respiratory syncytial virus (RSV) F, G, M2 (22K), and N proteins each induce resistance to RSV Challenge, but resistance induced by M2 and N proteins is relatively short-… [cited by applicant]
Cowton VM, McGivern DR, Fearns R. Unravelling the complexities of respiratory syncytial virus RNA synthesis. J Gen Virol. 2006;87(Pt 7):1805-1821. [cited by applicant]
Cullen, Lori M., Madelyn R. Schmidt, and Trudy G. Morrison. “The importance of RSV F protein conformation in VLPs in stimulation of neutralizing antibody titers in mice previously infected with RSV.” Human vaccines & im… [cited by applicant]
Esperante SA, Paris G, de Prat-Gay G. Modular unfolding and dissociation of the human respiratory syncytial virus phosphoprotein p and its interaction with the m(2-1) antiterminator: a singular tetramer-tetramer interfa… [cited by applicant]
Fearns R, Collins PL. Role of the M2-1 transcription antitermination protein of respiratory syncytial virus in sequential transcription. J Virol. 1999;73(7):5852-5864. [cited by applicant]
Graham BS. Immunological goals for respiratory syncytial virus vaccine development. Curr Opin Immunol. 2019;59:57-64. [cited by applicant]
Green CA, Scarselli E, Sande CJ, et al. Chimpanzee adenovirus- and MVA-vectored respiratory syncytial virus vaccine is safe and immunogenic in adults. Science translational medicine. 2015;7(300):300ra126. [cited by applicant]
Hall CB, Simoes EA, Anderson LJ. Clinical and epidemiologic features of respiratory syncytial virus. Curr Top Microbiol Immunol. 2013;372:39-57. [cited by applicant]
Hall CB, Weinberg GA, Iwane MK, et al. The burden of respiratory syncytial virus infection in young children. N Engl J Med. 2009;360(6):588-598. [cited by applicant]
Henikoff, Steven, and Jorja G. Henikoff. “Amino acid substitution matrices from protein blocks.” Proceedings of the National Academy of Sciences 89.22 (1992): 10915-10919. [cited by applicant]
Jartti T, Gern JE. Role of viral infections in the development and exacerbation of asthma in children. J Allergy Clin Immunol. 2017;140(4):895-906. [cited by applicant]
Jeong KI, Piepenhagen PA, Kishko M, et al. CX3CR1 Is Expressed in Differentiated Human Ciliated Airway Cells and Co-Localizes with Respiratory Syncytial Virus on Cilia in a G Protein-Dependent Manner. PLoS One. 2015;10(… [cited by applicant]
Johnson SM, McNally BA, Ioannidis I, et al. Respiratory Syncytial Virus Uses CX3CR1 as a Receptor on Primary Human Airway Epithelial Cultures. PLoS Pathog. 2015;11(12):e1005318. [cited by applicant]
Jorquera PA, Choi Y, Oakley KE, et al. Nanoparticle vaccines encompassing the respiratory syncytial virus (RSV) G protein CX3C chemokine motif induce robust immunity protecting from challenge and disease. PLoS One. 2013… [cited by applicant]
Karlin, Samuel, and Stephen F. Altschul. “Applications and statistics for multiple high-scoring segments in molecular sequences.” Proceedings of the National Academy of Sciences 90.12 (1993): 5873-5877. [cited by applicant]
Ke Z, Dillard RS, Chirkova T, et al. The Morphology and Assembly of Respiratory Syncytial Virus Revealed by Cryo-Electron Tomography. Viruses. 2018;10(8). [cited by applicant]
Kiss G, Holl JM, Williams GM, et al. Structural analysis of respiratory syncytial virus reveals the position of M2-1 between the matrix protein and the ribonucleoprotein complex. J Virol. 2014;88(13):7602-7617. [cited by applicant]
Krarup A, Truan D, Furmanova-Hollenstein P, et al. A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism. Nat Commun. 2015;6:8143. [cited by applicant]
Li D, Jans DA, Bardin PG, Meanger J, Mills J, Ghildyal R. Association of respiratory syncytial virus M protein with viral nucleocapsids is mediated by the M2-1 protein. J Virol. 2008;82(17):8863-8870. [cited by applicant]
Liu J, Haddad EK, Marceau J, et al. A Numerically Subdominant CD8 T Cell Response to Matrix Protein of Respiratory Syncytial Virus Controls Infection with Limited Immunopathology. PLoS Pathog. 2016;12(3):e1005486. [cited by applicant]
Lowy, Douglas R. “HPV vaccination to prevent cervical cancer and other HPV-associated disease: from basic science to effective interventions.” The Journal of clinical investigation 126.1 (2016): 5-11. [cited by applicant]
Matteucci, Mark Douglas, and M. Ho Caruthers. “Synthesis of deoxyoligonucleotides on a polymer support.” Journal of the American Chemical Society 103.11 (1981): 3185-3191. [cited by applicant]
Mazur NI, Higgins D, Nunes MC, et al. The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates. Lancet Infect Dis. 2018;18(10):e295-e311. [cited by applicant]
McLellan JS, Chen M, Joyce MG, et al. Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science. 2013;342(6158):592-598. [cited by applicant]
McLellan JS, Ray WC, Peeples ME. Structure and function of respiratory syncytial virus surface glycoproteins. Curr Top Microbiol Immunol. 2013;372:83-104. [cited by applicant]
Meshram CD, Baviskar PS, Ognibene CM, Oomens AG. The Respiratory Syncytial Virus Phosphoprotein, Matrix Protein, and Fusion Protein Carboxy-Terminal Domain Drive Efficient Filamentous Virus-Like Particle Formation. J Vi… [cited by applicant]
Moore ML, Chi MH, Luongo C, et al. A chimeric A2 strain of respiratory syncytial virus (RSV) with the fusion protein of RSV strain line 19 exhibits enhanced viral load, mucus, and airway dysfunction. J Virol. 2009;83(9)… [cited by applicant]
Murawski MR, McGinnes LW, Finberg RW, et al. Newcastle disease virus-like particles containing respiratory syncytial virus G protein induced protection in BALB/c mice, with no evidence of immunopathology. J Virol. 2010;… [cited by applicant]
Ngwuta JO, Chen M, Modjarrad K, et al. Prefusion F-specific antibodies determine the magnitude of RSV neutralizing activity in human sera. Science translational medicine. 2015;7(309):309ra162. [cited by applicant]
Quan FS, Kim Y, Lee S, et al. Viruslike particle vaccine induces protection against respiratory syncytial virus infection in mice. J Infect Dis. 2011;204(7):987-995. [cited by applicant]
Radu GU, Caidi H, Miao C, Tripp RA, Anderson LJ, Haynes LM. Prophylactic treatment with a G glycoprotein monoclonal antibody reduces pulmonary inflammation in respiratory syncytial virus (RSV)-challenged naive and forma… [cited by applicant]
Rey GU, Miao C, Caidi H, et al. Decrease in formalin-inactivated respiratory syncytial virus (FI-RSV) enhanced disease with RSV G glycoprotein peptide immunization in BALB/c mice. PLoS One. 2013;8(12):e83075. [cited by applicant]
Schepens B, Sedeyn K, Vande Ginste L, et al. Protection and mechanism of action of a novel human respiratory syncytial virus vaccine candidate based on the extracellular domain of small hydrophobic protein. EMBO Mol Med… [cited by applicant]
Schmidt, Madelyn R., et al. “Long-term and memory immune responses in mice against Newcastle disease virus-like particles containing respiratory syncytial virus glycoprotein ectodomains.” Journal of virology 86.21 (2012… [cited by applicant]
Schwarz B, Morabito KM, Ruckwardt TJ, et al. Viruslike Particles Encapsidating Respiratory Syncytial Virus M and M2 Proteins Induce Robust T Cell Responses. ACS Biomater Sci Eng. 2016;2(12):2324-2332. [cited by applicant]
Shaikh FY, Cox RG, Lifland AW, et al. A critical phenylalanine residue in the respiratory syncytial virus fusion protein cytoplasmic tail mediates assembly of internal viral proteins into viral filaments and particles. … [cited by applicant]
Shi T, McAllister DA, O'Brien KL, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review an… [cited by applicant]
Stockman LJ, Curns AT, Anderson LJ, Fischer-Langley G. Respiratory Syncytial Virus-associated Hospitalizations Among Infants and Young Children in the United States, 1997-2006. Pediatr Infect Dis J. 2012;31(1):5-9. [cited by applicant]
Stone AB. A simplified method for preparing sucrose gradients. Biochem J. 1974;137(1):117-118. [cited by applicant]
Tanner SJ, Ariza A, Richard CA, et al. Crystal structure of the essential transcription antiterminator M2-1 protein of human respiratory syncytial virus and implications of its phosphorylation. Proc Natl Acad Sci U S A.… [cited by applicant]
Tawar RG, Duquerroy S, Vonrhein C, et al. Crystal structure of a nucleocapsid-like nucleoprotein-RNA complex of respiratory syncytial virus. Science. 2009;326(5957):1279-1283. [cited by applicant]
Tripp RA, Power UF, Openshaw PJM, Kauvar LM. Respiratory Syncytial Virus: Targeting the G Protein Provides a New Approach for an Old Problem. J Virol. 2018;92(3). [cited by applicant]
Tripp RA. CX3C chemokine mimicry by respiratory syncytial virus G glycoprotein. In: Mahalingam S, ed. Chemokines in Viral Infection. Landes Bioscience; 2003. [cited by applicant]
Walpita P, Johns LM, Tandon R, Moore ML. Mammalian Cell-Derived Respiratory Syncytial Virus-Like Particles Protect the Lower as well as the Upper Respiratory Tract. PLoS One. 2015;10(7):e0130755. [cited by applicant]
Wu P, Hartert TV. Evidence for a causal relationship between respiratory syncytial virus infection and asthma. Expert Rev Anti Infect Ther. 2011;9(9):731-745. [cited by applicant]
Zhang W, Choi Y, Haynes LM, et al. Vaccination to induce antibodies blocking the CX3C-CX3CR1 interaction of respiratory syncytial virus G protein reduces pulmonary inflammation and virus replication in mice. J Virol. 20… [cited by applicant]